Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Names Executive to Lead Clinical Development of Co's Inflammation Programs

share with twitter share with LinkedIn share with facebook
share via e-mail
06/01/2020 | 04:54pm EDT

By Stephen Nakrosis

Gilead Sciences Inc. said Monday it named Mark Genovese to oversee the clinical development of its investigational portfolio of treatments for inflammatory conditions.

Dr. Genovese comes to Gilead from Stanford University, where he was on the faculty for more than 21 years and most recently served as the James W. Raitt Professor of Medicine and Clinical Chief in the Division of Immunology and Rheumatology, the company said.

Dr. Genovese, who was named as the company's SVP, Inflammation, will have responsibility "for the company's fibrosis clinical research programs including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis and systemic sclerosis," the company said.

Gilead said it is expanding its work in the field of inflammatory diseases, and added it has filed for regulatory approval in the U.S., Europe and Japan "of a potential treatment for rheumatoid arthritis, which, if approved, would be the company's first medicine to treat an inflammatory disease."

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. -0.70% 76.65 Delayed Quote.17.96%
THE LEAD CO., INC. 1.96% 365 End-of-day quote.-6.41%
THE NEW HOME COMPANY INC. 0.30% 3.4 Delayed Quote.-27.04%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
12:16pGlympse Bio Raises $46.7 Million in Series B Funding Round
DJ
07/13GILEAD SCIENCES : Pharmas restart drug trials after pandemic-related declines, M..
RE
07/13Stocks rise on hopes firms are set to bounce back
RE
07/13Assets start week on strong note; Polish zloty up after presidential results
RE
07/13GILEAD SCIENCES : JGBs slip as stronger equities dent safe-haven demand
RE
07/13S.Korean shares post sharpest gain in month on virus drug hopes
RE
07/13Nikkei marks 1-month closing high on virus drug hopes, autos gain
RE
07/13Australia, NZ end firmer on optimism around COVID-19 treatment, U.S. earnings
RE
07/13GILEAD SCIENCES : One in three South Korean COVID-19 patients improve with remde..
RE
07/12Nikkei rises on virus drug hopes, auto stocks surge
RE
More news
Financials (USD)
Sales 2020 23 176 M - -
Net income 2020 4 295 M - -
Net cash 2020 1 166 M - -
P/E ratio 2020 23,6x
Yield 2020 3,52%
Capitalization 96 148 M 96 148 M -
EV / Sales 2019
EV / Sales 2020 4,10x
Nbr of Employees 11 800
Free-Float 99,4%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 80,84 $
Last Close Price 76,65 $
Spread / Highest target 26,5%
Spread / Average Target 5,47%
Spread / Lowest Target -19,1%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.17.96%96 825
VERTEX PHARMACEUTICALS34.78%76 183
REGENERON PHARMACEUTICALS68.52%65 119
WUXI APPTEC CO., LTD.62.31%34 033
GENMAB A/S53.36%22 726
BIONTECH SE130.22%19 022